Background: Value-based pricing has the potential to contribute to the appropriate allocation of healthcare expenditures. We developed the "MARIE", a qualitative scheme that evaluates broad value elements without requiring a comparator to estimate new drug prices. In this study, we updated the conversion table that monetizes points calculated from value elements. Methods: We investigated and calculated the daily drug prices at the time of listing for drugs containing new active ingredients that were included in the National Health Insurance Drug Price List from fiscal year 2015 to 2024, summarizing the data using descriptive statistics. Results: New drug prices are listed annually in Japan, so we updated the conversion table using current drug prices to maintain continuity. This study also observed a trend where the median daily price tended to be higher as the maximum number of patients decreased. Conclusions: The MARIE method, our developed framework to qualitatively evaluate the various values of drugs, monetizing points calculated based on the elements of value via the conversion table, plays a crucial role. Updating the conversion table based on the latest data maintains continuity with the current drug pricing system and is considered to contribute to the social implementation of the MARIE method.